These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 9816199

  • 1. Synergistic interaction between cisplatin and gemcitabine in vitro.
    Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ.
    Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ.
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [Abstract] [Full Text] [Related]

  • 3. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ.
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [Abstract] [Full Text] [Related]

  • 4. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM.
    Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
    [Abstract] [Full Text] [Related]

  • 5. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJ, Vermorken JB, Postmus PE, Peters GJ.
    Biochem Pharmacol; 1999 Feb 15; 57(4):407-15. PubMed ID: 9933029
    [Abstract] [Full Text] [Related]

  • 6. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
    Yang LY, Li L, Jiang H, Shen Y, Plunkett W.
    Clin Cancer Res; 2000 Mar 15; 6(3):773-81. PubMed ID: 10741696
    [Abstract] [Full Text] [Related]

  • 7. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
    Padrón JM, van Moorsel CJ, Bergman AM, Smitskamp-Wilms E, van der Wilt CL, Peters GJ.
    Anticancer Drugs; 1999 Jun 15; 10(5):445-52. PubMed ID: 10477163
    [Abstract] [Full Text] [Related]

  • 8. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
    Van Moorsel CJ, Smid K, Voorn DA, Bergman AM, Pinedo HM, Peters GJ.
    Int J Oncol; 2003 Jan 15; 22(1):201-7. PubMed ID: 12469205
    [Abstract] [Full Text] [Related]

  • 9. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ.
    Biochem Pharmacol; 1994 Oct 07; 48(7):1327-39. PubMed ID: 7945430
    [Abstract] [Full Text] [Related]

  • 10. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
    van Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, Lakerveld B, Van der Vijgh WJ, Giaccone G, Postmus PE, Peters GJ.
    Eur J Cancer; 2000 Dec 07; 36(18):2420-9. PubMed ID: 11094319
    [Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy studies with gemcitabine.
    van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, Peters GJ.
    Semin Oncol; 1997 Apr 07; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
    [Abstract] [Full Text] [Related]

  • 12. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
    van Bree C, Castro Kreder N, Loves WJ, Franken NA, Peters GJ, Haveman J.
    Int J Radiat Oncol Biol Phys; 2002 Sep 01; 54(1):237-44. PubMed ID: 12182997
    [Abstract] [Full Text] [Related]

  • 13. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ.
    Eur J Cancer; 2000 Oct 01; 36(15):1974-83. PubMed ID: 11000580
    [Abstract] [Full Text] [Related]

  • 14. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters G.
    Biochem Pharmacol; 1996 Apr 12; 51(7):911-8. PubMed ID: 8651941
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.
    Honeywell RJ, Ruiz van Haperen VW, Veerman G, Smid K, Peters GJ.
    Int J Biochem Cell Biol; 2015 Mar 12; 60():73-81. PubMed ID: 25562513
    [Abstract] [Full Text] [Related]

  • 16. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines.
    Voigt W, Bulankin A, Müller T, Schoeber C, Grothey A, Hoang-Vu C, Schmoll HJ.
    Clin Cancer Res; 2000 May 12; 6(5):2087-93. PubMed ID: 10815936
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
    van Moorsel CJ, Bergman AM, Veerman G, Voorn DA, Ruiz van Haperen VW, Kroep JR, Pinedo HM, Peters GJ.
    Biochim Biophys Acta; 2000 Mar 06; 1474(1):5-12. PubMed ID: 10699484
    [Abstract] [Full Text] [Related]

  • 18. Role of 2'-2' difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas.
    Rosier JF, Bruniaux M, Husson B, Octave-Prignot M, Beauduin M, Grégoire V.
    Radiother Oncol; 2004 Jan 06; 70(1):55-61. PubMed ID: 15036853
    [Abstract] [Full Text] [Related]

  • 19. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.
    Ruiz van Haperen VW, Veerman G, Vermorken JB, Peters GJ.
    Biochem Pharmacol; 1993 Aug 17; 46(4):762-6. PubMed ID: 8363650
    [Abstract] [Full Text] [Related]

  • 20. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ.
    Biochem Pharmacol; 2001 Jun 01; 61(11):1401-8. PubMed ID: 11331076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.